Last reviewed · How we verify
lipid-lowering treatment
The lipid-lowering treatment developed by Kumamoto University is currently marketed, positioning it as an established player in the cholesterol management market. A key strength of the drug is its composition patent, which is set to expire in 2028, providing a period of exclusive market protection. The primary risk is the potential increase in competition following the patent expiry, which could erode market share and revenue.
At a glance
| Generic name | lipid-lowering treatment |
|---|---|
| Sponsor | Kumamoto University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- A Prospective, Open, Observational Study to Confirm the Lipid-lowering Effect, Changes in Glucose Metabolism, and Safety After 6 Months of Administration of Atostazet to Hypercholesterolemic Patients 65 Years of Age or Older
- Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy
- Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)
- Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
- Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC (PHASE1)
- Metformin Safety and Efficacy in Osteoarthritis. (PHASE3)
- The Belgian REAL (BE.REAL) Registry
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lipid-lowering treatment CI brief — competitive landscape report
- lipid-lowering treatment updates RSS · CI watch RSS
- Kumamoto University portfolio CI